Steven Shilling
Cardiovascular Disease · Irving, TXNPI 1629077524
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $323,731 of the $324,198 with a category attached, or 99.9%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 92.4% of it on its own, with 1 other manufacturer making up the rest. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $1953.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$299K
- Shire North American Group Inc$25K
What the payments were for
- Consulting fees$323,731100%
- Travel & lodging$4670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 154 | $299,478 |
| Shire North American Group Inc | 12 | $24,720 |
How this compares
$324,198 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Irving
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.